{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:05:44Z","timestamp":1793379944374,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ECS00000017-THE"],"award-info":[{"award-number":["ECS00000017-THE"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ebiom.2025.105577","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:04:27Z","timestamp":1738656267000},"page":"105577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4585-7783","authenticated-orcid":false,"given":"Annalisa","family":"Ciabattini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-8061","authenticated-orcid":false,"given":"Fabio","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-0546","authenticated-orcid":false,"given":"Jacopo","family":"Polvere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7102-2724","authenticated-orcid":false,"given":"Simone","family":"Costagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabiria","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sicuranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bucalossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Garosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Bernazzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Medaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.105577_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11904-019-00461-6","article-title":"Hepatitis B vaccination and waning hepatitis B immunity in persons living with HIV","volume":"16","author":"Farooq","year":"2019","journal-title":"Curr HIV AIDS Rep"},{"key":"10.1016\/j.ebiom.2025.105577_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100775","article-title":"Vaccination for patients receiving dialysis","volume":"6","author":"Sam","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.ebiom.2025.105577_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006599","article-title":"A\u00a0third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with\u00a0low antibody response after 2 doses","author":"Pettini","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2025.105577_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017863","article-title":"The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients","volume":"13","author":"Fiorino","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib5","first-page":"1480","article-title":"The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose","volume":"9","author":"Fiorino","year":"2021","journal-title":"Biomedicine"},{"key":"10.1016\/j.ebiom.2025.105577_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s43856-023-00245-5","article-title":"B\u00a0cell response after SARS-CoV-2 mRNA vaccination in people living with HIV","volume":"3","author":"Polvere","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.ebiom.2025.105577_bib7","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a\u00a0systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ebiom.2025.105577_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104788","article-title":"Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-\u03b1-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation","volume":"96","author":"Garner-Spitzer","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2025.105577_bib9","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S1473-3099(23)00357-2","article-title":"Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients","volume":"23","author":"Solera","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105577_bib10","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S1473-3099(23)00783-1","article-title":"Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany","volume":"24","author":"Cossmann","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105577_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740708","article-title":"Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine","volume":"12","author":"Ciabattini","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/cells12131706","article-title":"Trajectory of spike-specific B cells elicited by two doses of BNT162b2 mRNA vaccine","volume":"12","author":"Ciabattini","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ebiom.2025.105577_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","volume":"185","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2025.105577_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/imcb.12635","article-title":"T\u00a0follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults","volume":"101","author":"Boyd","year":"2023","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.ebiom.2025.105577_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","article-title":"Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination","volume":"55","author":"Gao","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2025.105577_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/vaccines12040368","article-title":"Spike-specific memory B cell response in hematopoietic cell transplantation recipients following multiple mRNA-1273 vaccinations: a longitudinal observational study","volume":"12","author":"Pettini","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.ebiom.2025.105577_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104700","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID","volume":"94","author":"Chen","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.ebiom.2025.105577_bib18","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41591-023-02414-4","article-title":"SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease","volume":"29","author":"Barnes","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2025.105577_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.889138","article-title":"SARS-CoV-2-mRNA booster vaccination reverses non-responsiveness and early antibody waning in immunocompromised patients\u2014a phase four study comparing immune responses in patients with solid cancers, multiple myeloma and inflammatory bowel disease","volume":"13","author":"Wagner","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib20","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.45.2200125","article-title":"Tracking the progressive spread of the SARS-CoV-2 omicron variant in Italy, december 2021 to january 2022","volume":"27","author":"Stefanelli","year":"2022","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.ebiom.2025.105577_bib22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A\u00a0SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ebiom.2025.105577_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cyto.a.20258","article-title":"A\u00a0new \u201cLogicle\u201d display method avoids deceptive effects of logarithmic scaling for low signals and compensated data","volume":"69A","author":"Parks","year":"2006","journal-title":"Cytometry Part A"},{"key":"10.1016\/j.ebiom.2025.105577_bib24","first-page":"2579","article-title":"Viualizing data using t-SNE","volume":"9","author":"van der Maaten","year":"2008","journal-title":"J\u00a0Mach Learn Res"},{"key":"10.1016\/j.ebiom.2025.105577_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/01621459.1987.10478478","article-title":"Sample size determination for some common nonparametric tests","volume":"82","author":"Noether","year":"1987","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.ebiom.2025.105577_bib27","first-page":"119","article-title":"Integrase inhibitors use and cytomegalovirus infection predict immune recovery in people living with HIV starting first-line therapy","volume":"86","author":"Fabbiani","year":"2021","journal-title":"JAIDS"},{"key":"10.1016\/j.ebiom.2025.105577_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100984","article-title":"SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies","volume":"56","author":"Ni","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.ebiom.2025.105577_bib29","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3390\/biomedicines10112892","article-title":"Non-myelofibrosis chronic myeloproliferative neoplasm patients show better seroconversion rates after SARS-CoV-2 vaccination compared to other hematologic diseases: a multicentric prospective study of KroHem","volume":"10","author":"Serti\u0107","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ebiom.2025.105577_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B Cell-Depleted patients after Rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892331","article-title":"Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients","volume":"13","author":"Pascale","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/vaccines12050518","article-title":"Breakthrough infections in SARS-CoV-2-vaccinated multiple myeloma patients improve cross-protection against omicron variants","volume":"12","author":"Wagner","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2025.105577_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.852158","article-title":"Seroconversion to mRNA SARS-CoV-2 vaccines in hematologic patients","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2025.105577_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26305","article-title":"Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib","author":"Guglielmelli","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ebiom.2025.105577_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.826537","article-title":"Impaired antibody response following the second dose of the BNT162b2 vaccine in patients with myeloproliferative neoplasms receiving ruxolitinib","volume":"9","author":"Ikeda","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.ebiom.2025.105577_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1117815","article-title":"Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine","volume":"13","author":"Palumbo","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ebiom.2025.105577_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/14760584.2024.2333952","article-title":"Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant","volume":"23","author":"Pastore","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ebiom.2025.105577_bib39","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1016\/j.vaccine.2015.04.008","article-title":"HIV-associated memory B cell perturbations","volume":"33","author":"Hu","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2025.105577_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1146\/annurev-immunol-093019-125603","article-title":"Transcriptional and metabolic control of memory B cells and plasma cells","volume":"39","author":"Ripperger","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","article-title":"Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans","volume":"57","author":"Tortorici","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2025.105577_bib42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/QAD.0000000000003263","article-title":"Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV","volume":"36","author":"Woldemeskel","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.ebiom.2025.105577_bib43","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3390\/vaccines11121739","article-title":"Long term assessment of anti-SARS-CoV-2 immunogenicity after mRNA vaccine in persons living with HIV","volume":"11","author":"Vergori","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ebiom.2025.105577_bib44","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cit937","article-title":"Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis","volume":"58","author":"Kern\u00e9is","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105577_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009732","article-title":"Germinal Center T follicular helper (GC-Tfh) cell impairment in chronic HIV infection involves c-Maf signaling","volume":"17","author":"Chakhtoura","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ebiom.2025.105577_bib46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib47","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/infdis\/jiad152","article-title":"Susceptibility to SARS-CoV-2 infection and immune responses to COVID-19 vaccination among recipients of solid organ transplants","volume":"228","author":"Subramanian","year":"2023","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105577_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888385","article-title":"Risk factors for weak antibody response of SARS-CoV-2 vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis","volume":"13","author":"Zong","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib49","first-page":"4125","article-title":"Increasing antibody responses to five doses of SARS-CoV-2 mRNA vaccine in lung transplant patients","volume":"12","author":"van Gemert","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ebiom.2025.105577_bib50","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.1003319","article-title":"Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation","volume":"187","author":"Karnell","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib51","article-title":"Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom","volume":"25","author":"Hyams","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ebiom.2025.105577_bib52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2025.105577_bib53","doi-asserted-by":"crossref","first-page":"e883","DOI":"10.1016\/S2666-5247(23)00194-5","article-title":"Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"4","author":"Stadler","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ebiom.2025.105577_bib54","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41467-024-45050-3","article-title":"Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:16:31Z","timestamp":1762618591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":52,"alternative-id":["S2352396425000210"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105577","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105577"}}